Our current study showed that breast cancer patients who received neoadjuvant chemotherapy showed higher plasma levels of lipopolysaccharide-binding protein as an indicator of circulating proinflammatory LPS levels compared to treatment-naïve patients. This evidence concerns the gene LBP and breast carcinoma.